Remove Bioinformatics Remove Drug Delivery Remove In-Vivo Remove Production
article thumbnail

What to expect from PEGS Europe 2023: Day 2

Drug Discovery World

The first three include: Sungjin Park, PhD, CEO, Onegene Biotechnology, on: ‘UniStac: Enzyme-mediated conjugation technology for accelerated development of tetraspecific NASH drug’. Croasdale-Wood will then participate in a keynote chat, interviewed by Miho.

article thumbnail

What to expect from PEGS Europe 2023: Day 1

Drug Discovery World

Sebastian Jaeger, PhD, Senior Scientist, ADCs & Targeted NBE Therapeutics, Merck Healthcare KGaA, on: ‘Evaluation of Fcab-drug conjugates as a novel antibody-based format for targeted drug delivery’. Marketing Product Manager, Product, NanoTemper Technologies.